Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Despite a lower enrollment rate for October we continue to see strong performance across trial sites for screening. Our sites are eager to ...

These changes were accompanied by disruptions in the gut microbiota, with a notable increase in Proteobacteria, a major source of gut-derived endotoxic lipopolysaccharide (LPS). Such disruptions ...

Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.

Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" ...